Brief: Prometheus Biosciences Receives FDA Clearance Of Ind Application For Its Second Precision Program, PRA052
03/10/2022 13:56
Oct 3 (Reuters) - Prometheus Biosciences Inc RXDX.O :
* PROMETHEUS BIOSCIENCES RECEIVES FDA CLEARANCE OF IND
APPLICATION
FOR ITS SECOND PRECISION PROGRAM, PRA052
* PROMETHEUS BIOSCIENCES INC - INITIATION OF PHASE 1 STUDY
OF
PRA052 EXPECTED IN 4Q 2022
Source text for Eikon: ID:nGNX7hF15n
Further company coverage: RXDX.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Prometheus Biosciences
See all newsBrief: Prometheus Biosciences - Completed Merger Of Splash Merger Sub, Unit Of Merck & Co
Analysis: Amgen's antitrust woes spur wider pharmaceutical deal fears
William Blair sees FTC suit on Amgen-Horizon deal weighing on biotech M&A sentiment
FTC scrutiny to block Amgen-Horizon deal drags down Seagen, Prometheus
Brief: Prometheus Biosciences Reports First Quarter 2023 Financial Results